Similarly, we examined the effects of IL-6 in patients with advanced cancer, particularly ovarian cancer, and found that its deleterious effects must be counteracted at all stages of metastatic neoplastic disease [25–28, 63]. Here, IL6 is linked to ovarian cancer.